Thermo Fisher Scientific Announces Next-Generation Sequencing Oncomine Focus Assay for Oncology Research

Translational and clinical research laboratories now have access to a multi-biomarker, next-generation sequencing (NGS) panel that includes 52 solid tumor genes associated with current oncology drugs and published evidence. The Oncomine Focus Assay by Thermo Fisher Scientific (NYSE: TMO) is being featured at the American Association for Cancer Research conference taking place April 18-22 at the Pennsylvania Convention Center in Philadelphia.


Combined with a simplified workflow and favorable economics for detection of relevant genes, this new next-generation sequencing assay further expands the capability of translational and clinical research laboratories, allowing them to advance precision oncology within their own communities and improve the future of cancer care.

Labcritics Alerts / Sign-up to get alerts on discounts, new products, apps, protocols and breakthroughs in tools that help researchers succeed.